Epithelica is a pioneering Berlin-based biotech specializing in non-invasive, one-time gene therapies for severe genetic skin diseases. The patented platform uses laser-assisted skin microporation with optimized lipid nanoparticles to deliver gene editors for durable, mutation-specific correction backed by strong preclinical efficacy and safety. Scalable to 500+ diseases, it offers curative, cost-saving care and positions Epithelica as a global leader in precision dermatology.